Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Cardiovascular Diseases × Lymphoid × Clear all
NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Merck Sharp & Dohme LLC

Phase 3 Completed
637 enrolled 15 charts
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell